Zoetis Inc. $ZTS Stock Position Lifted by Prudential PLC

Prudential PLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 17.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 197,852 shares of the company’s stock after buying an additional 29,702 shares during the quarter. Prudential PLC’s holdings in Zoetis were worth $28,950,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. CIBC Asset Management Inc increased its holdings in Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after buying an additional 10,434 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its stake in Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after acquiring an additional 18,040 shares during the last quarter. Ninety One UK Ltd grew its position in Zoetis by 19.6% in the third quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after acquiring an additional 183,686 shares in the last quarter. Quilter Plc grew its position in Zoetis by 10.2% in the third quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after acquiring an additional 40,615 shares in the last quarter. Finally, Swedbank AB increased its stake in shares of Zoetis by 60.4% during the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock worth $356,565,000 after purchasing an additional 917,598 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

ZTS opened at $115.62 on Friday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The stock’s 50 day moving average price is $125.34 and its two-hundred day moving average price is $131.91. The firm has a market capitalization of $48.81 billion, a P/E ratio of 19.21, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95. Zoetis Inc. has a 12-month low of $114.47 and a 12-month high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion during the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.Zoetis’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s dividend payout ratio is 35.22%.

Analysts Set New Price Targets

ZTS has been the topic of a number of recent research reports. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday. Stifel Nicolaus lowered their target price on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Piper Sandler restated a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. UBS Group set a $136.00 price target on Zoetis in a research report on Thursday, January 29th. Finally, KeyCorp started coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Six equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.